Abstract
Angiogenesis is crucial for tumor development, growth and metastasis. Vascular endothelial growth factor (VEGF) has been implicated in promoting solid tumor growth and metastasis via stimulating tumor-associated angiogenesis, and blocking the activity of VEGF can starve tumors. Avastin, which is a humanized anti-VEGF antibody, has been successfully applied in clinics since 2004. However, the price of Avastin is extremely high for Chinese people. Here, we report a novel human anti-VEGF neutralizing antibody, MIL60, which shows an affinity comparable to that of Avastin (the KD value of MIL60 was 44.5 pM, while that of Avastin was 42.7 pM). MIL60 displays favorable actions in inhibiting VEGF-triggered endothelial cell proliferation (the IC50 value of MIL60 was 31±6.4 ng/ml and that of Avastin was 47±8.1 ng/ml), migration (8 µg/ml or 0.8 µg/ml MIL60 versus the control: P<0.05) and tube formation (2 µg/ml or 0.2 µg/ml MIL60 versus the control: P<0.05) via the VEGFR2 signaling pathway. Moreover, MIL60 was shown to inhibit tumor growth and angiogenesis in vivo in xenograft models of human colon carcinoma and ovarian cancer using immunotherapy and immunohistochemistry analysis (MIL60 versus N.S.: P=0.0007; Avastin versus N.S.: P=0.00046). These data suggest that MIL60 is a potential therapeutic, anti-angiogenic agent. Our work provides a novel anti-VEGF antibody, which can be considered an anti-tumor antibody candidate and a new option for patients with various cancers.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 digital issues and online access to articles
$119.00 per year
only $9.92 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Carmeliet P, Jain RK . Molecular mechanisms and clinical applications of angiogenesis. Nature 2011; 473: 298–307.
Ichihara E, Kiura K, Tanimoto M . Targeting angiogenesis in cancer therapy. Acta Med Okayama 2011; 65: 353–362.
Ferrara N . Molecular and biological properties of vascular endothelial growth factor. J Mol Med (Berl) 1999; 77: 527–543.
Klagsbrun M, D'Amore PA . Vascular endothelial growth factor and its receptors. Cytokine Growth Factor Rev 1996; 7: 259–270.
Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z . Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 1999; 13: 9–22.
Prewett M, Huber J, Li Y, Santiago A, O'Connor W, King K et al. Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors. Cancer Res 1999; 59: 5209–5218.
Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993; 362: 841–844.
Gerber HP, Kowalski J, Sherman D, Eberhard DA, Ferrara N . Complete inhibition of rhabdomyosarcoma xenograft growth and neovascularization requires blockade of both tumor and host vascular endothelial growth factor. Cancer Res 2000; 60: 6253–6258.
Konner J, Dupont J . Use of soluble recombinant decoy receptor vascular endothelial growth factor trap (VEGF Trap) to inhibit vascular endothelial growth factor activity. Clin Colorectal Cancer 2004; 4( Suppl 2): S81–S85.
Ferrara N, Hillan KJ, Gerber HP, Novotny W . Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 2004; 3: 391–400.
Gasparini G, Longo R, Toi M, Ferrara N . Angiogenic inhibitors: a new therapeutic strategy in oncology. Nat Clin Pract Oncol 2005; 2: 562–577.
Ferrara N, Kerbel RS . Angiogenesis as a therapeutic target. Nature 2005; 438: 967–974.
Jain RK, Duda DG, Clark JW, Loeffler JS . Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol 2006; 3: 24–40.
McTigue M, Murray BW, Chen JH, Deng YL, Solowiej J, Kania RS . Molecular conformations, interactions, and properties associated with drug efficiency and clinical performance among VEGFR TK inhibitors. Proc Natl Acad Sci USA 2012; 109: 18281–18289.
Sullivan LA, Brekken RA . The VEGF family in cancer and antibody-based strategies for their inhibition. MAbs 2010; 2: 165–175.
Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335–2342.
Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006; 355: 2542–2550.
Brooks BR, Brooks CL 3rd, Mackerell AD Jr, Nilsson L, Petrella RJ, Roux B et al. CHARMM: the biomolecular simulation program. J Comput Chem 2009; 30: 1545–1614.
Maeda K, Chung YS, Ogawa Y, Takatsuka S, Kang SM, Ogawa M et al. Prognostic value of vascular endothelial growth factor expression in gastric carcinoma. Cancer 1996; 77: 858–863.
Weidner N, Folkman J, Pozza F, Bevilacqua P, Allred EN, Moore DH et al. Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. J Natl Cancer Inst 1992; 84: 1875–1887.
Higgins B, Kolinsky K, Linn M, Adames V, Zhang YE, Moisa C et al. Antitumor activity of capecitabine and bevacizumab combination in a human estrogen receptor-negative breast adenocarcinoma xenograft model. Anticancer Res 2007; 27: 2279–2287.
Martiny-Baron G, Korff T, Schaffner F, Esser N, Eggstein S, Marme D et al. Inhibition of tumor growth and angiogenesis by soluble EphB4. Neoplasia 2004; 6: 248–257.
Qiao C, Lv M, Li X, Geng J, Li Y, Zhang J et al. Affinity maturation of antiHER2 monoclonal antibody MIL5 using an epitope-specific synthetic phage library by computational design. J Biomol Struct Dyn 2013; 31: 511–521.
Papadopoulos N, Martin J, Ruan Q, Rafique A, Rosconi MP, Shi E et al. Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis 2012; 15: 171–185.
Presta LG, Chen H, O'Connor SJ, Chisholm V, Meng YG, Krummen L et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 1997; 57: 4593–4599.
Kim KJ, Li B, Houck K, Winer J, Ferrara N . The vascular endothelial growth factor proteins: identification of biologically relevant regions by neutralizing monoclonal antibodies. Growth Factors 1992; 7: 53–64.
Ng EW, Shima DT, Calias P, Cunningham ET Jr, Guyer DR, Adamis AP . Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. Nat Rev Drug Discov 2006; 5: 123–132.
Yu Y, Lee P, Ke Y, Zhang Y, Yu Q, Lee J et al. A humanized anti-VEGF rabbit monoclonal antibody inhibits angiogenesis and blocks tumor growth in xenograft models. PLoS ONE 2010; 5: e9072.
Ferla R, Bonomi M, Otvos L Jr, Surmacz E . Glioblastoma-derived leptin induces tube formation and growth of endothelial cells: comparison with VEGF effects. BMC Cancer 2011; 11: 303.
Wang Y, Fei D, Vanderlaan M, Song A . Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro. Angiogenesis 2004; 7: 335–345.
Jain RK . Antiangiogenic therapy for cancer: current and emerging concepts. Oncology (Williston Park) 2005; 19: 7–16.
Gerber HP, Wu X, Yu L, Wiesmann C, Liang XH, Lee CV et al. Mice expressing a humanized form of VEGF-A may provide insights into the safety and efficacy of anti-VEGF antibodies. Proc Natl Acad Sci USA 2007; 104: 3478–3483.
Acknowledgements
This work was supported by grants from the National Sciences Fund (Nos. 31370938 and 81272528) and the National High Technology Research and Development Program (863 Program, No. 2012AA02A302).
Author information
Authors and Affiliations
Additional information
Supplementary Information accompanies the paper on Cellular & Molecular Immunology's website. (http://www.nature.com/cmi).
Supplementary information
Rights and permissions
About this article
Cite this article
Yang, J., Wang, Q., Qiao, C. et al. Potent anti-angiogenesis and anti-tumor activity of a novel human anti-VEGF antibody, MIL60. Cell Mol Immunol 11, 285–293 (2014). https://doi.org/10.1038/cmi.2014.6
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/cmi.2014.6
Keywords
This article is cited by
-
Antibody-mediated biorecognition of myelin oligodendrocyte glycoprotein: computational evidence of demyelination-related epitopes
Scientific Reports (2019)
-
Selection and characterization of the novel anti-human PD-1 FV78 antibody from a targeted epitope mammalian cell-displayed antibody library
Cellular & Molecular Immunology (2018)